查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1136996

免疫查核点抑制剂市场:各药物类别，各流通管道，各地区-规模，占有率，展望，机会分析，2022～2030年

Immune Checkpoint Inhibitors Market, by Drug Class (Programmed Death Receptor-1 Inhibitors (Pembrolizumab, Nivolumab, Cemiplimab, & Others), Distribution Channel, & Region - Size, Share, Outlook, & Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 238 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场动态

癌症患病率的上升预计将推动全球免疫检查点抑製剂市场。

本调查的主要特征

  • 本报告提供以2021年为基准年的预测期间（2022-2030 年）之全球免疫查核点抑制剂市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
  • 并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
  • 同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
  • 并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球免疫查核点抑制剂市场的主要参与者之企业简介。
  • 藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 全球免疫查核点抑制剂市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以透过全球免疫查核点抑制剂市场用于分析的各种战略矩阵来帮助他们更容易做下决策。

目录

第1章 调查目的与前提条件

  • 调查目的
  • 前提条件
  • 简称的说明

第2章 市场展望

  • 报告内容
    • 市场定义和范围
  • 摘要整理
    • 市场概述:各药物类别
    • 市场概述:各癌症类型
    • 市场概述:各销售管道
    • 市场概述:各地区
  • 连贯机遇地图(COM)

第3章 市场动态，法规，及趋势的分析

  • 市场动态
    • 促进因素
    • 阻碍因素
    • 市场机会
  • 影响分析
  • 流行病学
  • 合作和伙伴关係
  • 主要的FDA核准与产品上市情景
  • 开发平台分析
  • 药事法规情景
  • 保险偿付情景
  • PEST分析
  • 波特的五力分析

第4章 免疫查核点抑制剂的全球市场-冠状病毒(COVID-19)疫情的影响

  • 整体影响
  • 政府的配合措施
  • COVID-19市场的影响

第5章 免疫查核点抑制剂的全球市场，各药物类别，2017年～2030年

  • 程序性死亡受体-1(PD-1)抑制剂
  • 市场规模，预测，Yo-Y成长率，2017年～2030年
  • 市场规模，预测，与前一年同期比较成长率，2017-2030年
  • 市场规模，预测，与前一年同期比较成长率，2017-2030年
  • 市场规模，预测，与前一年同期比较成长率，2017年～2030年
  • 程序性死亡受体1(PD-L1)抑制剂
  • 市场规模，预测，与前一年同期比较成长率，2017-2030年
  • PD-L1抑制剂的市场规模，预测，与前一年同期比较成长率，2017-2030年
  • 市场规模，预测，与前一年同期比较成长率，2017-2030年
  • CTL-4查核点抑制剂
  • 市场规模，预测，与前一年同期比较成长率，2017-2030年
  • 吲哚胺-2,3-双加氧酶(IDO)抑制剂
  • 淋巴球活性化遗传基因3抑制剂

第6章 免疫查核点抑制剂的全球市场(癌症类别):2017年～2030年

  • 肺癌症
  • 头颈椎癌症
  • 皮肤癌症(黑色素瘤，默克尔细胞癌)
  • 血液癌症(淋巴瘤)
  • 膀胱癌(尿道表皮癌症)
  • 肾臟癌
  • 大肠癌
  • 乳癌
  • 其他

第7章 免疫查核点抑制剂的全球市场，各流通管道，2017年～2030年

  • 医院内药局
  • 零售药局
  • 线上药局

第8章 免疫查核点抑制剂的全球市场:各地区，2017年～2030年

  • 北美
  • 美国
  • 加拿大
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他的南美地区
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 中东地区
  • GCC
  • 以色列
  • 其他的中东地区
  • 非洲
  • 北非
  • 中非
  • 南非

第9章 竞争情形

  • 热图分析
  • 企业简介
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.

第10章 章节

  • 参考文献
  • 调查手法
简介目录
Product Code: CMI2560

Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients' immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

The rise in prevalence of cancer is expected to drive the global immune checkpoint inhibitors market. For instance, according to the American Cancer Society, in 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases, and 3,210,000 and 640,000 cancer deaths in China and the USA, respectively. Estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.)

Key features of the study:

  • This report provides an in-depth analysis of the global immune checkpoint inhibitors market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global immune checkpoint inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immune checkpoint inhibitors market

Detailed Segmentation:

  • Global Immune Checkpoint Inhibitors Market, By Drug Class:
    • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
    • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
    • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
    • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    • Lymphocyte-Activation Gene 3 Inhibitors
  • Global Immune Checkpoint Inhibitors Market, By Cancer Type:
    • Lung Cancer
    • Head & Neck Cancer
    • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    • Blood Cancer (Lymphoma)
    • Bladder Cancer (Urothelial Carcinoma)
    • Renal/Kidney Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Others
  • Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Immune Checkpoint Inhibitors Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Bristol-Myers Squibb Company*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Merck & Co., Inc.
    • Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Cancer Type
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Epidemiology
  • Collaborations & Partnerships
  • Major FDA Approvals & Product Launch Scenario
  • Pipeline Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • PEST Analysis
  • Porter's Five Forces Analysis

4. Global Immune Checkpoint Inhibitors Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Immune Checkpoint Inhibitors Market, By Drug Class, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Programmed Death Receptor-1 (PD-1) Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Pembrolizumab (Keytruda)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Nivolumab (Opdivo)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Cemiplimab (Libtayo)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Programmed Death-Ligand 1 (PD-L1) Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Atezolizumab (Tecentriq)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Avelumab (Bavencio)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Durvalumab (Imfinzi)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • CTL-4 Checkpoint Inhibitor
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
    • Ipilimumab (Yervoy)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Lymphocyte-Activation Gene 3 Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Immune Checkpoint Inhibitors Market, By Cancer Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Lung Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Head & Neck Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Blood Cancer (Lymphoma)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Bladder Cancer (Urothelial Carcinoma)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Renal/Kidney Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Colorectal Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Breast Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Immune Checkpoint Inhibitors Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Immune Checkpoint Inhibitors Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact